Table 3.
Multivariate analysis with multiple imputations 2008–2016.
| HR a | 95% CI | p Value | |
|---|---|---|---|
| Age | 0.3876 | ||
| <70 years | 1.00 | ||
| ≥70 years | 1.05 | 0.93–1.19 | |
| Gender | 0.0886 | ||
| Female | 1.00 | ||
| Male | 1.10 | 0.98–1.23 | |
| PS | <0.0001 | ||
| 0–1 | 1.00 | ||
| ≥2 | 1.83 | 1.39–2.40 | |
| LDH | <0.0001 | ||
| Below ULN | 1.00 | ||
| Above ULN | 1.91 | 1.77–2.12 | |
| Stage | |||
| M1a | 1.00 | ||
| M1b | 1.27 | 1.01–1.61 | 0.0385 |
| M1c | 1.79 | 1.49–2.16 | <0.0001 |
| M1d | 2.64 | 2.14–3.28 | <0.0001 |
| Melanoma type | |||
| Cutaneous | 1.00 | ||
| Mucosal | 1.20 | 0.90–1.61 | 0.2071 |
| Ocular | 1.57 | 1.18–2.09 | 0.0016 |
| Unknown primary | 1.02 | 0.86–1.21 | 0.8156 |
| Any anti-CTLA-4 or anti-PD1 therapy b | <0.0001 | ||
| No | 1.00 | ||
| Yes | 0.39 | 0.35–0.44 |
a Cox regression analysis, p < 0.05 in univariate analyses as entry; b anytime during their treatment course. HR = hazard ratio; CI = confidence interval; PS = performance status; ULN = upper level of normal.